Abstract
Dr Li has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device. Researchers from The Netherlands recently evaluated the efficacy and safety of the bivalent HPV vaccine (Cervarix) administered at 0, 1, and 6 months in females aged 12 to 18 years with juvenile idiopathic arthritis [JIA] compared to healthy controls (HC).1 Immunogenicity was determined by measuring the level of HPV-specific IgG antibodies (reported as geometric mean concentration [GMC]) to calculate the seropositivity rate at 7 and 12 months after the first vaccination. Investigators also measured memory B cell responses before the first vaccination and 3, 7, and 12 months afterwards in a subset of JIA and …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
